Blockade of the high-affinity noradrenaline transporter (NET) by the selective 5-HT reuptake inhibitor escitalopram: An in vivo microdialysis study in mice

British Journal of Pharmacology

Volumn 168, Issue 1, 2013, Pages 103-116

  Nguyen, Hai T ^a   Guiard, Bruno P ^a   Bacq, Alexandre ^b,c,d   David, Denis J ^a   David, Indira ^a   Quesseveur, Gaël ^a   Gautron, Sophie ^b,c,d   Sanchez, Connie ^e   Gardier, Alain M ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSERM   (France)

^c Groupe Enzymologie Moléculaire et Fonctionnelle   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e H LUNDBECK A S   (Denmark)

Author keywords

5 HT selective reuptake inhibitor; 5 HT transporter; antidepressant; behaviour; escitalopram; frontal cortex; intracerebral microdialysis

Indexed keywords

ESCITALOPRAM; NORADRENALIN; NORADRENALIN TRANSPORTER; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING AFFINITY; CLIMBING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL TEST; FORCED SWIM TEST; FRONTAL CORTEX; IN VIVO STUDY; MALE; MICRODIALYSIS; MOUSE; MUTANT; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; CEREBRAL CORTEX; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FRONTAL LOBE; MALE; MICE; MICRODIALYSIS; MODELS, ANIMAL; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SWIMMING; SYNAPTIC TRANSMISSION;

EID: 84864188983     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01850.x     Document Type: Article

References (88)

1. Alexander S, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Amphoux A, Vialou V, Drescher E, Brüss M, Mannoury La Cour C, Rochat C, et al,. (2006). Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 50: 941-952.
3. Bacq A, Balasse L, Biala G, Guiard B, Gardier AM, Schinkel A, et al,. (2011). Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response. Mol Psychiatry 17: 926-939.
4. Baganz NL, Horton RE, Calderon AS, Owens WA, Munn JL, Watts LT, et al,. (2008). Organic cation transporter 3: keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice. Proc Natl Acad Sci U S A 105: 18976-18981.
5. Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A, et al,. (1998). Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ('Ecstasy') in serotonin transporter-deficient mice. Mol Pharmacol 53: 649-655.
6. Bert L, Favale D, Jego G, Greve P, Guilloux JP, Guiard BP, et al,. (2004). Rapid and precise method to locate microdialysis probe implantation in the rodent brain. J Neurosci Methods 140: 53-57.
7. Berton O, Nestler EJ, (2006). New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7: 137-151.
8. Beyer CE, Boikess S, Luo B, Dawson LA, (2002). Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J Psychopharmacol 16: 297-304.
9. Blakely RD, De Felice LJ, (2007). All aglow about presynaptic receptor regulation of neurotransmitter transporters. Mol Pharmacol 71: 1206-1208.
10. Borgkvist A, Malmlöf T, Feltmann K, Lindskog M, Schilström B, (2011). Dopamine in the hippocampus is cleared by the norepinephrine transporter. Int J Neuropsychopharmacol 15: 531-540.
11. Breidert T, Spitzenberger F, Gründemann D, Schömig E, (1998). Catecholamine transport by the organic cation transporter type 1 (OCT1). Br J Pharmacol 125: 218-224.
12. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, et al,. (2002). Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) 160: 353-361.
13. Calcagno E, Canetta A, Guzzetti S, Cervo L, Invernizzi RW, (2007). Strain differences in basal and post-citalopram extracellular 5-HT in the mouse medial prefrontal cortex and dorsal hippocampus: relation with tryptophan hydroxylase-2 activity. J Neurochem 103: 1111-1120.
14. Carboni E, Tanda GL, Frau R, Di Chiara G, (1990). Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55: 1067-1070.
15. Ceglia I, Acconcia S, Fracasso C, Colovic M, Caccia S, Invernizzi RW, (2004). Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors. Br J Pharmacol 142: 469-478.
16. Cervo L, Canetta A, Calcagno E, Burbassi S, Sacchetti G, Caccia S, et al,. (2005). Genotype-dependent activity of tryptophan hydroxylase-2 determines the response to citalopram in a mouse model of depression. J Neurosci 25: 8165-8172.
17. Cryan JF, Lucki I, (2000). Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors. J Pharmacol Exp Ther 295: 1120-1126.
18. Cryan JF, Page ME, Lucki I, (2002). Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. Eur J Pharmacol 436: 197-205.
19. Cryan JF, O'Leary OF, Jin SH, Frieldland JC, Ouyang M, Hirsch BR, et al,. (2004). Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc Natl Acad Sci U S A 101: 8186-8191.
20. Dahlin A, Xia L, Kong W, Hevner R, Wang J, (2007). Expression and immunolocalization of the plasma membrane monoamine transporter in the brain. Neuroscience 146: 1193-1211.
21. David DJ, Bourin M, Jego G, Przybylski C, Jolliet P, Gardier AM, (2003). Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. Br J Pharmacol 140: 1128-1136.
22. Detke MJ, Rickels M, Lucki I, (1995). Active behaviours in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 121: 66-72.
23. Dremencov E, El Mansari M, Blier P, (2007). Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry 61: 671-678.
24. Duan H, Wang J, (2010). Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther 335: 743-753.
25. Dulawa SC, Holick KA, Gundersen B, Hen R, (2004). Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 29: 1321-1330.
26. El Mansari M, Sanchez C, Chouvet G, Renaud B, Haddjeri N, (2005). Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 30: 1269-1277.
27. Engel K, Wang J, (2005). Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol Pharmacol 68: 1397-1407.
28. Engel K, Zhou M, Wang J, (2004). Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem 279: 50042-50049.
29. Feng N, Mo B, Johnson PL, Orchinik M, Lowry CA, Renner KJ, (2005). Local inhibition of organic cation transporters increases extracellular serotonin in the medial hypothalamus. Brain Res 1063: 69-76.
30. Feng N, Lowry CA, Lukkes JL, Orchinik M, Forster GL, Renner KJ, (2010). Organic cation transporter inhibition increases medial hypothalamic serotonin under basal conditions and during mild restraint. Brain Res 1326: 105-113.
31. -/- mice. Eur J Neurosci 28: 1195-1204.
32. Frazer A, (2001). Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. J Clin Psychiatry 62 (Suppl. 12): 16-23.
33. Garnock-Jones KP, McCormack PL, (2010). Escitalopram: a review of its use in the management of major depressive disorder in adults. CNS Drugs 24: 769-796.
34. Gether U, Andersen PH, Larsson OM, Schousboe A, (2006). Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol Sci 27: 375-383.
35. Grundemann D, Koster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, et al,. (1998a). Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem 273: 30915-30920.
36. Grundemann D, Schechinger B, Rappold GA, Schomig E, (1998b). Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci 1: 349-351.
37. Guiard BP, Przybylski C, Guilloux JP, Seif I, Froger N, De Felipe C, et al,. (2004). Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. J Neurochem 89: 54-63.
38. Guiard BP, El Mansari M, Blier P, (2008a). Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus. Mol Pharmacol 74: 1463-1475.
39. Guiard BP, El Mansari M, Merali Z, Blier P, (2008b). Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol 11: 625-639.
40. Guilloux JP, David DJ, Guiard BP, Chenu F, Reperant C, Toth M, et al,. (2006). Blockade of 5-HT1A receptors by (+/-)-pindolol potentiates cortical 5-HT outflow, but not antidepressant-like activity of paroxetine: microdialysis and behavioral approaches in 5-HT1A receptor knockout mice. Neuropsychopharmacology 31: 2162-2172.
41. Haenisch B, Bönisch H, (2010). Interaction of the human plasma membrane monoamine transporter (hPMAT) with antidepressants and antipsychotics. Naunyn Schmiedebergs Arch Pharmacol 381: 33-39.
42. Hajos-Korcsok E, McQuade R, Sharp T, (1999). Influence of 5-HT1A receptors on central noradrenergic activity: microdialysis studies using (+/-)-MDL 73005EF and its enantiomers. Neuropharmacology 38: 299-306.
43. Hayer-Zillgen M, Brüss M, Bönisch H, (2002). Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol 136: 829-836.
44. Hof PR, Young WG, Bloom FE, Belichenko PV, Celio MR, (2000). Comparative Cytoarchitectonic Atlas of the C57BL/6 and 129/Sv Mouse Brains with CD ROM. Elsevier: San Diego, CA.
45. Holick KA, Lee DC, Hen R, Dulawa SC, (2008). Behavioural effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology 33: 406-417.
46. Hughes ZA, Stanford SC, (1996). Increased noradrenaline efflux induced by local infusion of fluoxetine in the rat frontal cortex. Eur J Pharmacol 317: 83-90.
47. Hughes ZA, Stanford SC, (1998). Evidence from microdialysis and synaptosomal studies of rat cortex for noradrenaline uptake sites with different sensitivities to SSRIs. Br J Pharmacol 124: 1141-1148.
48. Invernizzi R, Bramante M, Samanin R, (1995). Extracellular concentrations of serotonin in the dorsal hippocampus after acute and chronic treatment with citalopram. Brain Res 696: 62-66.
49. Jacquot C, David DJ, Gardier AM, Sanchez C, (2007). Escitalopram and citalopram: the unexpected role of the R-enantiomer. Encephale 33: 179-187.
50. Jordan S, Kramer GL, Zukas PK, Moeller M, Petty F, (1994). In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse 18: 294-297.
51. Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, et al,. (1998). Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem 273: 15971-15979.
52. Kennedy SH, Andersen HF, Thase ME, (2009). Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 25: 161-175.
53. Kobayashi K, Ikeda Y, Haneda E, Suzuki H, (2008). Chronic fluoxetine bidirectionally modulates potentiating effects of serotonin on the hippocampal mossy fiber synaptic transmission. J Neurosci 28: 6272-6280.
54. Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP, (2002). R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology 27: 949-959.
55. Koepsell H, Lips K, Volk C, (2007). Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24: 1227-1251.
56. Kornstein SG, Li D, Mao Y, Larsson S, Andersen HF, Papakostas GI, (2009). Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials. CNS Spectr 14: 326-333.
57. Kreilgaard M, Smith DG, Brennum LT, Sanchez C, (2008). Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice. Br J Pharmacol 155: 276-284.
58. Miguelez C, Fernandez-Aedo I, Torrecilla M, Grandoso L, Ugedo L, (2009). alpha(2)-Adrenoceptors mediate the acute inhibitory effect of fluoxetine on locus coeruleus noradrenergic neurons. Neuropharmacology 56: 1068-1073.
59. Miguelez C, Grandoso L, Ugedo L, (2011). Locus coeruleus and dorsal raphe neuron activity and response to acute antidepressant administration in a rat model of Parkinson's disease. Int J Neuropsychopharmacol 14: 187-200.
60. Millan MJ, Gobert A, Lejeune F, Newman-Tancredi A, Rivet JM, Auclair A, et al,. (2001). S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298: 565-580.
61. Mongeau R, De Montigny C, Blier P, (1994). Effect of long-term administration of antidepressant drugs on the 5-HT3 receptors that enhance the electrically evoked release of [3H]noradrenaline in the rat hippocampus. Eur J Pharmacol 271: 121-129.
62. Mongeau R, Blier P, de Montigny C, (1997). The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Res Brain Res Rev 23: 145-195.
63. Mork A, Kreilgaard M, Sanchez C, (2003). The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45: 167-173.
64. Morõn JA, Brockington A, Wise RA, Rocha BA, Hope BT, (2002). Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22: 389-395.
65. Nutt DJ, (2002). The neuropharmacology of serotonin and noradrenaline in depression. Int Clin Psychopharmacol 17 (Suppl. 1): S1-12.
66. Owens MJ, Knight DL, Nemeroff CB, (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50: 345-350.
67. Page ME, Detke MJ, Dalvi A, Kirby LG, Lucki I, (1999). Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl) 147: 162-167.
68. Perez XA, Bianco LE, Andrews AM, (2006). Filtration disrupts synaptosomes during radiochemical analysis of serotonin uptake: comparison with chronoamperometry in SERT knockout mice. J Neurosci Methods 154: 245-255.
69. Porsolt RD, Le Pichon M, Jalfre M, (1977). Depression: a new animal model sensitive to antidepressant treatments. Nature 266: 730-732.
70. Pudovkina OL, Cremers TI, Westerink BH, (2002). The interaction between the locus coeruleus and dorsal raphe nucleus studied with dual-probe microdialysis. Eur J Pharmacol 445: 37-42.
71. Rainer Q, Xia L, Guilloux JP, Gabriel C, Mocaër E, Hen R, et al,. (2011). Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. Int J Neuropsychopharmacol 81: 106-112.
72. Reneric JP, Lucki I, (1998). Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology (Berl) 136: 190-197.
73. Richardson-Jones JW, Craige CP, Guiard BP, Stephen A, Metzger KL, Kung HF, et al,. (2010). 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron 65: 40-52.
74. Richelson E, Pfenning M, (1984). Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104: 277-286.
75. Sanchez C, Hyttel J, (1999). Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19: 467-489.
76. Sanchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, et al,. (2003a). Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 167: 353-362.
77. Sanchez C, Gruca P, Papp M, (2003b). R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 14: 465-470.
78. Shachar D, Klein E, Tabak A, Finberg JP, (1997). Effect of single and repeated administration of fluvoxamine on noradrenaline release in rat brain. Eur J Pharmacol 332: 237-243.
79. Szabo ST, Blier P, (2001a). Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res 922: 9-20.
80. Szabo ST, Blier P, (2001b). Serotonin (1A) receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABA(A) receptors: a microiontophoretic study in the rat locus coeruleus. Synapse 42: 203-212.
81. Tatsumi M, Groshan K, Blakely RD, Richelson E, (1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340: 249-258.
82. Thomas DR, Nelson DR, Johnson AM, (1987). Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl) 93: 193-200.
83. Uhr M, Grauer MT, (2003). abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 37: 179-185.
84. Vialou V, Amphoux A, Zwart R, Giros B, Gautron S, (2004). Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci 24: 2846-2851.
85. Vialou V, Balasse L, Callebert J, Launay JM, Giros B, Gautron S, (2008). Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice. J Neurochem 106: 1471-1482.
86. Vizi ES, Zsilla G, Caron MG, Kiss JP, (2004). Uptake and release of norepinephrine by serotonergic terminals in norepinephrine transporter knock-out mice: implications for the action of selective serotonin reuptake inhibitors. J Neurosci 24: 7888-7894.
87. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, et al,. (2000). Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol 279: F449-F458.
88. Zomkowski AD, Engel D, Gabilan NH, Rodrigues AL, (2010). Involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effects of escitalopram in the forced swimming test. Eur Neuropsychopharmacol 20: 793-801.